APO RESEARCH · REPORT
Oligonucleotide Therapeutics
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Product & engineering
Understand the product.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Selected research
Industry Growth & Trends
Global Oligonucleotide Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
According to APO Research, the global Oligonucleotide Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Oligonucleotide Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Oligonucleotide Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oligonucleotide Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oligonucleotide Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Oligonucleotide Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Oligonucleotide Therapeutics Market by Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Oligonucleotide Therapeutics Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Oligonucleotide Therapeutics Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Oligonucleotide Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oligonucleotide Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Antisense Oligonucleotide
- Aptamer
- Other
Applications
- Neuromuscular Diseases
- ATTR
- Hepatic VOD
- Other
Companies covered
- Biogen
- Sarepta Therapeutics
- Jazz Pharmaceuticals
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Dynavax Technologies
- Kastle therapeutics
- Akcea Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Oligonucleotide Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Oligonucleotide Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Oligonucleotide Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Oligonucleotide Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Oligonucleotide Therapeutics Market Size (2021-2032)
- 1.5.1 North America Oligonucleotide Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Oligonucleotide Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Oligonucleotide Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Oligonucleotide Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Oligonucleotide Therapeutics Market Size Growth Rate (2021-2032)
2 Oligonucleotide Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Antisense Oligonucleotide
- 2.1.2 Aptamer
- 2.1.3 Other
- 2.2 Global Oligonucleotide Therapeutics Market Size by Type
- 2.2.1 Global Oligonucleotide Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Oligonucleotide Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Oligonucleotide Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Oligonucleotide Therapeutics Market Size by Regions
- 2.3.1 North America Oligonucleotide Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Oligonucleotide Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Oligonucleotide Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Oligonucleotide Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Oligonucleotide Therapeutics Market Size Breakdown by Type (2021-2026)
3 Oligonucleotide Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Neuromuscular Diseases
- 3.1.2 ATTR
- 3.1.3 Hepatic VOD
- 3.1.4 Other
- 3.2 Global Oligonucleotide Therapeutics Market Size by Application
- 3.2.1 Global Oligonucleotide Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Oligonucleotide Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Oligonucleotide Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Oligonucleotide Therapeutics Market Size by Regions
- 3.3.1 North America Oligonucleotide Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Oligonucleotide Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Oligonucleotide Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Oligonucleotide Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Oligonucleotide Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Oligonucleotide Therapeutics Industry Trends
- 4.2 Oligonucleotide Therapeutics Industry Drivers
- 4.3 Oligonucleotide Therapeutics Industry Opportunities and Challenges
- 4.4 Oligonucleotide Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Oligonucleotide Therapeutics Revenue (2021-2026)
- 5.2 Global Oligonucleotide Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Oligonucleotide Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Oligonucleotide Therapeutics Company, Product Type & Application
- 5.5 Global Oligonucleotide Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Oligonucleotide Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Oligonucleotide Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Oligonucleotide Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Biogen
- 6.1.1 Biogen Company Information
- 6.1.2 Biogen Business Overview
- 6.1.3 Biogen Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
- 6.1.5 Biogen Recent Developments
- 6.2 Sarepta Therapeutics
- 6.2.1 Sarepta Therapeutics Company Information
- 6.2.2 Sarepta Therapeutics Business Overview
- 6.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
- 6.2.5 Sarepta Therapeutics Recent Developments
- 6.3 Jazz Pharmaceuticals
- 6.3.1 Jazz Pharmaceuticals Company Information
- 6.3.2 Jazz Pharmaceuticals Business Overview
- 6.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
- 6.3.5 Jazz Pharmaceuticals Recent Developments
- 6.4 Bausch & Lomb
- 6.4.1 Bausch & Lomb Company Information
- 6.4.2 Bausch & Lomb Business Overview
- 6.4.3 Bausch & Lomb Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
- 6.4.5 Bausch & Lomb Recent Developments
- 6.5 Alnylam Pharmaceuticals
- 6.5.1 Alnylam Pharmaceuticals Company Information
- 6.5.2 Alnylam Pharmaceuticals Business Overview
- 6.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
- 6.5.5 Alnylam Pharmaceuticals Recent Developments
- 6.6 Dynavax Technologies
- 6.6.1 Dynavax Technologies Company Information
- 6.6.2 Dynavax Technologies Business Overview
- 6.6.3 Dynavax Technologies Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
- 6.6.5 Dynavax Technologies Recent Developments
- 6.7 Kastle therapeutics
- 6.7.1 Kastle therapeutics Company Information
- 6.7.2 Kastle therapeutics Business Overview
- 6.7.3 Kastle therapeutics Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
- 6.7.5 Kastle therapeutics Recent Developments
- 6.8 Akcea Therapeutics
- 6.8.1 Akcea Therapeutics Company Information
- 6.8.2 Akcea Therapeutics Business Overview
- 6.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
- 6.8.5 Akcea Therapeutics Recent Developments
7 North America
- 7.1 North America Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Oligonucleotide Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Oligonucleotide Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Oligonucleotide Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Oligonucleotide Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Oligonucleotide Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst